Objective: Faecal microbiota transplantation (FMT) from healthy donors to patients with irritable bowel syndrome (IBS) has been attempted in two previous double-blind, placebo-controlled studies. While one of those studies found improvement of the IBS symptoms, the other found no effect. The present study was conducted to clarify these contradictory findings.
Design: This randomised, double-blind, placebo-controlled study randomised 165 patients with IBS to placebo (own faeces), 30 g FMT or 60 g FMT at a ratio of 1:1:1. The material for FMT was obtained from one healthy, well-characterised donor, frozen and administered via gastroscope. The primary outcome was a reduction in the IBS symptoms at 3 months after FMT (response). A response was defined as a decrease of 50 or more points in the total IBS symptom score. The secondary outcome was a reduction in the dysbiosis index (DI) and a change in the intestinal bacterial profile, analysed by 16S rRNA gene sequencing, at 1 month following FMT.
Results: Responses occurred in 23.6%, 76.9% (p<0.0001) and 89.1% (p<00.0001) of the patients who received placebo, 30 g FMT and 60 g FMT, respectively. These were accompanied by significant improvements in fatigue and the quality of life in patients who received FMT. The intestinal bacterial profiles changed also significantly in the groups received FMT. The FMT adverse events were mild self-limiting gastrointestinal symptoms.
Conclusions: FMT is an effective treatment for patients with IBS. Utilising a well-defined donor with a normal DI and favourable specific microbial signature is essential for successful FMT. The response to FMT increases with the dose. Trial registration www.clinicaltrials.gov (NCT03822299) and www.cristin.no (ID657402).
Keywords: colonic microflora; irritable bowel syndrome; lactobacillus.
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Faecal Microbiota Transplantation Alters Gut Microbiota in Patients With Irritable Bowel Syndrome: Results From a Randomised, Double-Blind Placebo-Controlled StudySI Halkjær et al. Gut 67 (12), 2107-2115. PMID 29980607. - Randomized Controlled TrialIn this randomised double-blinded placebo-controlled study, we found that FMT changed gut microbiota in patients with IBS. But patients in the placebo group experienced g …
Faecal Microbiota Transplantation Versus Placebo for Moderate-To-Severe Irritable Bowel Syndrome: A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Single-Centre TrialPH Johnsen et al. Lancet Gastroenterol Hepatol 3 (1), 17-24. PMID 29100842. - Randomized Controlled TrialHelseNord and the Norwegian Centre of Rural Medicine, University of Tromsø.
Faecal Microbiota Transplantation for Diarrhoea-Predominant Irritable Bowel Syndrome: A Double-Blind, Randomised, Placebo-Controlled TrialOC Aroniadis et al. Lancet Gastroenterol Hepatol 4 (9), 675-685. PMID 31326345.National Institutes of Health.
Systematic Review With Meta-Analysis: Efficacy of Faecal Microbiota Transplantation for the Treatment of Irritable Bowel SyndromeG Ianiro et al. Aliment Pharmacol Ther 50 (3), 240-248. PMID 31136009. - ReviewFresh or frozen donor stool delivered via colonoscopy or nasojejunal tube may be beneficial in IBS. Larger, more rigorously conducted trials of FMT in IBS are needed.
Fecal Microbiota Transplantation for Managing Irritable Bowel SyndromeM El-Salhy et al. Expert Rev Gastroenterol Hepatol 12 (5), 439-445. PMID 29493330. - ReviewIrritable bowel syndrome (IBS) is a widespread gastrointestinal disorder affecting 11.2% of the world adult population. The intestinal microbiome is thought to play a piv …